

*Siegars*  
*198 also*

**WHAT IS CLAIMED IS:**

- 323 Sub  
136 C*
- 1        1. An embolizing composition comprising:
    - 2            (a) from about 2.5 to about 8.0 weight percent of an ethylene
    - 3            vinyl alcohol copolymer embolizing agent;
    - 4            (b) from about 10 to about 40 weight percent of a water
    - 5            insoluble contrast agent selected from the group consisting of tantalum,
    - 6            tantalum oxide and barium sulfate;
    - 7            (c) from about 52 to about 87.5 weight percent of a
    - 8            biocompatible solvent

9            wherein the weight percent of each of the components is based on

10          the total weight of the complete composition.
  - 1        2. The embolizing composition according to Claim 1 wherein
  - 2        said ethylene vinyl alcohol copolymer comprises from about 25 to about 60
  - 3        mole percent of ethylene and from about 40 to about 75 mole percent of
  - 4        vinyl alcohol.
  - 1        3. The embolizing composition according to Claim 2 wherein
  - 2        said biocompatible solvent is DMSO.
  - 1        4. The embolizing composition according to Claim 3 wherein
  - 2        said contrast agent is tantalum.
  - 1        5. The embolizing composition according to Claim 3 wherein
  - 2        said contrast agent is tantalum oxide.
  - 1        6. The embolizing composition according to Claim 3 wherein
  - 2        said contrast agent is barium sulfate.

1           7. A method for embolizing a blood vessel by injecting into  
2        said blood vessel a sufficient amount of an embolizing composition  
3        comprising:

4           (a) from about 2.5 to about 8.0 weight percent of an ethylene  
5        vinyl alcohol copolymer embolizing agent;

6           (b) from about 10 to about 40 weight percent of a water  
7        insoluble contrast agent selected from the group consisting of tantalum,  
8        tantalum oxide and barium sulfate;

9           (c) from about 52 to about 87.5 weight percent of a  
10      biocompatible solvent

11          wherein the weight percent of each of the components is based on  
12      the total weight of the complete composition

13          under conditions wherein a precipitate is formed which embolizes  
14      the blood vessel.

1           8. The method according to Claim 7 wherein said ethylene  
2        vinyl alcohol copolymer comprises from about 25 to about 60 mole percent  
3        of ethylene and from about 40 to about 75 mole percent of vinyl alcohol.

1           9. The method according to Claim 8 wherein said biocompatible  
2        solvent is DMSO.

1           10. The method according to Claim 9 wherein said contrast agent  
2        is tantalum.

1           11. The method according to Claim 9 wherein said contrast agent  
2        is tantalum oxide.

1           12. The method according to Claim 9 wherein said contrast agent  
2        is barium sulfate.

1           13. The method according to Claim 7 wherein the embolizing  
2       composition is injected into the blood vessel at a rate of about 0.05 to 0.3  
3       cc/minute.

1           14. The method according to Claim 7 wherein the embolizing  
2       composition is injected into the blood vessel at a rate of at least 0.6  
3       cc/minute.

1           15. The method according to Claim 14 wherein the injection rate  
2       of at least 0.6 cc/minute is employed to form a filament like mass  
3       projecting down stream from the catheter tip for embolizing tumor masses,  
4       organs and arteriovenous malformations (AVM).

22